Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.3500
+0.0600 (20.69%)
Apr 2, 2026, 4:00 PM EST
Avenue Therapeutics Revenue
In the year 2025, Avenue Therapeutics had annual revenue of $1.40M.
Revenue
1.40M
Revenue Growth
n/a
P/S Ratio
0.82
Revenue / Employee
702.00K
Employees
2
Market Cap
1.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Carisma Therapeutics | 52.63M |
| Evofem Biosciences | 20.18M |
| Emmaus Life Sciences | 12.45M |
| International Stem Cell | 9.10M |
| Scorpius Holdings | 1.72M |
| Lyra Therapeutics | 398.00K |
| Eastgate Biotech | 137.64K |
Avenue Therapeutics News
- 1 year ago - Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 2 years ago - Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - GlobeNewsWire
- 2 years ago - Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 years ago - Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds - GlobeNewsWire